Samsung Biologics eyes peptide market with billion-dollar takeover bid

Samsung Biologics announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group AG, a leading global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs). Un...